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High-risk human papillomavirus (HR-HPV) infection-associated cancers of the cervix, anogeni-
tal tract, and the nasopharynx represent an important clinical problem globally (1, 2). Mucosal 
HPV infections are highly prevalent; however, only a very small subset of HR-HPV infections 
persists and a small fraction these persistent infections will, in fact, lead to cancer development 
(3). Moreover, HPV-induced carcinogenesis takes many years or decades to develop and is a 
multistep process that requires additional tumor-promoting factors for invasive cancer to occur 
(3). It is now accepted that the immune system has a key surveillance function that can prevent 
persistent HPV infections and can also control the neoplastic transformation and the progression 
of premalignant lesions to invasive carcinoma (4, 5). Currently used regimens for the treatment 
of HPV-associated cancers have remained unchanged for decades and are of limited value for 
the treatment of patients with advanced or recurrent disease (6). The available prophylactic vac-
cines can protect against infections by the most common HR-HPV types, but they are not able 
to eliminate or prevent the malignant progression of persistent HPV infections (5). Therefore, 
immune-based therapies are considered as promising novel approaches for the prevention and 
effective treatment of HPV-associated diseases.
The key viral factors that are involved in the induction and maintenance of the malignant phe-
notype of the host cell are the HR-HPV E6 and E7 proteins (7, 8). These early HPV oncoproteins 
do not possess enzymatic activity, but rather manipulate the host cell by associating with a plethora 
of cellular proteins (9, 10). The main biological function of these interactions is to hinder the dif-
ferentiation of the infected epithelial cell and keep it in a replication-competent state to ensure HPV 
genome replication. However, during HPV-associated carcinogenesis, HR-HPV E6 and E7 can also 
contribute to all of the main phenotypic alterations of malignant cells that have been named as 
“hallmarks of cancer” (11).
Both E6 and E7 represent ideal targets for immunotherapy, as they are immunologically foreign 
antigens. Furthermore, they are always retained and constitutively expressed by HPV-positive cancer 
cells as growth is strongly dependent on sustained E6/E7 expression (“oncogene addiction”) that 
ensures the continuous inactivation of tumor suppressor pathways. E6/E7 levels cannot be down-
regulated as an immune-evasion mechanism, because their inhibition leads to induction of irrevers-
ible proliferative arrest (cellular senescence) (11) (Figure 1). Moreover, a recent large-scale genomic 
survey suggests that the conserved sequence of E7 oncoprotein is critical for cervical carcinogenesis 
(12). Nevertheless, efforts to induce tumor regression by targeting the E6 and/or E7 oncoproteins by 
using immunotherapy, such as different types of therapeutic vaccines, had limited success (6, 13).
Recent evidence supports the importance of targeting non-viral antigens in immunotherapy 
of HPV-associated cervical cancer (14, 15). The continuous expression of HPV oncoproteins can 
FIGUre 1 | Oxygenation can change the biological behavior of 
HPV-positive tumors. Impaired mechanistic target of rapamycin (mTOR) 
signaling and concomitant HPV E6/E7 repression in hypoxic HPV-
positive cancer cells allow the evasion of senescence. This has several 
clinical implications for the treatment of HPV-associated cancers: (1) 
dormant HPV-positive cancer cells in hypoxic subregions of tumors 
might lead to cancer recurrence if oxygen supply increases; (2) the 
growth inhibition under hypoxic conditions in cancer tissues results in 
increased therapeutic resistance against pro-senescent 
chemotherapeutic agents; (3) reduced expression of viral E6/E7 
oncoproteins could represent a major obstacle for immunotherapy of 
HPV-associated cancers.
2
Szalmás Hypoxia Affects HPV Oncogene Expression
Frontiers in Oncology | www.frontiersin.org March 2018 | Volume 8 | Article 77
cause genomic instability, which can subsequently lead to an 
increased somatic mutation rate and aberrations in the epige-
netic regulation of tissue-specific gene expression. The altered 
protein products of somatic mutations (mutated neoantigens) 
and the aberrantly expressed epigenetically dysregulated genes 
(cancer germline antigens) may also elicit an effective immune 
response and, therefore, represent an additional immune-based 
therapeutic strategy against HPV-associated malignancies. 
A recent study demonstrated that in two patients with complete 
remission of HPV infection-associated metastatic cervical 
cancer after adoptive therapy with tumor infiltrating T lympho-
cytes (TILs), immunodominant T cell reactivities were directed 
against mutated neoantigens or a cancer germline antigen, 
rather than the HPV-specific antigens (16). This was observed 
in spite of the fact that the T  cells used for adoptive therapy 
were selected for HPV antigen reactivity. Moreover, analysis 
of peripheral blood samples revealed that TILs against viral 
antigens did not show preferential in  vivo expansion during 
cancer regression.
The above-mentioned article can provide a possible explana-
tion for the limited efficacy of HPV antigen-specific immuno-
therapy and the lower than anticipated presence of HPV-specific 
TILs following adoptive immunotherapy (17). Hoppe-Seyler 
and colleagues made the remarkable observation that under 
hypoxic conditions that are often found in advanced stage 
cervical cancer as well as oral squamous cell carcinoma tissues, 
the expression of HPV E6/E7 viral oncoproteins is strongly 
downregulated. First, they observed that under hypoxia, HR 
HPV-positive cervical cancer cell lines show decreased expres-
sion of HPV E6/E7 oncogenes. They also observed a decreased 
E7 expression in hypoxic areas of HPV-16 positive cervical 
cancer tissue specimens. Interestingly, E6/E7 downregulation 
by hypoxia did not lead to the induction of cellular senes-
cence in HPV-positive cervical cancer cells, instead, the cells 
underwent a reversible mitotic and growth arrest (dormancy) 
(Figure 1). Upon re-oxygenation, these dormant HPV-positive 
cells restored E6/E7 expression, which led to renewal of host 
cell proliferation.
They propose that the key metabolic pathway that ensures the 
induction of senescence upon E6/E7 downregulation under nor-
moxia is the mechanistic target of rapamycin (mTOR) signaling 
pathway. Treatment of HPV-positive cancer cells with mTOR 
inhibitors released them from HPV oncoprotein “addiction,” 
thus, enabled the escape of cancer cells from senescence when 
E6/E7 expression is blocked. Next, they demonstrated that the 
lack of senescence induction observed in HPV-positive cancer 
cells cultured under hypoxic conditions is because of impaired 
mTOR signaling. In hypoxic HPV-18-positive HeLa cells, the 
hypoxia-inducible factor 1 downstream target regulated in 
development and DNA damage responses 1 (REDD1) was 
upregulated. REDD1 can interfere with mTOR signaling via 
activation of the mTOR inhibitor tuberous sclerosis complex 2 
(TSC2); therefore, the authors propose that the REDD1/TSC2 
axis might be responsible for the lack of senescence induction in 
hypoxic HeLa cells. Impairment of mTOR signaling by hypoxia 
(similarly to treatment with mTOR inhibitors) interfered with 
the senescence response of HPV-positive cancer cells against 
pro-senescent chemotherapeutic agents. The findings of this 
study demonstrate that the clinical outcome in patients with 
HPV-associated cancers can be strongly influenced by the 
metabolic state of the host cell (Figure  1). Thus, prospective 
pro-senescent E6/E7 inhibitors would be expected to have 
therapeutic potential in normoxic cancer cells with elevated 
E6/E7 expression and active mTOR signaling. However, to 
target HPV-positive cancer cells in hypoxic tumor sub-areas, 
viral oncoprotein inhibition could be combined with other 
approaches specifically targeting hypoxic cells/tissue regions or 
applying hypoxia-activated agents (18–21).
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